Pharmaust Limited (AU:NUZ) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurizon Therapeutics Limited has issued 400,000 fully paid ordinary shares following the exercise of unlisted options, priced at $0.10 each. This move, part of their broader strategy to accelerate treatments for ALS and other neurodegenerative diseases, underscores Neurizon’s commitment to advancing its lead drug candidate NUZ-001. The company remains compliant with relevant corporate regulations, ensuring transparency in its financial operations.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.